WO1996014748A1 - AMELIORATION OF HUMAN ERECTILE DYSFUNCTION BY TREATMENT WITH iNOS, AND RELATED NOS AGENTS - Google Patents
AMELIORATION OF HUMAN ERECTILE DYSFUNCTION BY TREATMENT WITH iNOS, AND RELATED NOS AGENTS Download PDFInfo
- Publication number
- WO1996014748A1 WO1996014748A1 PCT/US1995/014588 US9514588W WO9614748A1 WO 1996014748 A1 WO1996014748 A1 WO 1996014748A1 US 9514588 W US9514588 W US 9514588W WO 9614748 A1 WO9614748 A1 WO 9614748A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inos
- penile
- cdna
- tissue
- erectile dysfunction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
- C12N9/0075—Nitric-oxide synthase (1.14.13.39)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
- C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- TITLE AMELIORATION OF HUMAN ERECTILE DYSFUNCTION BY TREATMENT WITH iNOS, AND RELATED NOS AGENTS
- This invention relates to a treatment of erectile dysfunction, and more specifically to the treatment of erectile dysfunction by use of inducible Nitric Oxide Synthase (iNOS) agents, including INOS, NOS isoforms, inducers of iNOS, iNOS cDNAand recombinant iNOS cDNA-transformed penile smooth muscle cells (iNOS engineered cells), for the purpose of ameliorating erectile vasculogenic dysfunction in the penis, typically vasculogenic dysfunction.
- iNOS is induced in vivo e.g., in penile corpora cavernosa, to produce penile tissue specific expression of increased levels of iNOS for amelioration of the patient's condition.
- iNOS may be induced in vitro in excised and cultured corpora cavernosa cells, extracted, purified and thereafter provided to patients in a wide variety of delivery systems.
- recombinant iNOS can be synthesized in vitro and delivered to the patient for treatment.
- cDNA iNOS may be introduced in patient penile tissue to produce recombinant iNOS in vivo.
- the ex vivo cultured cells can be transformed with penile iNOS and or NOS isoform cDNA, and the resultant genetically engineered cells introduced into the corpora cavernosa in vivo.
- Other NOS isoforms or their respective cDNAs and recombinant proteins, and penile cells transfected by the NOS cDNAs may be employed using the same procedures described for iNOS.
- Impotence the inability to obtain or maintain a penile erection sufficient for sexual intercourse, afflicts more than 12 million men in the USA. It is associated with aging and occurs in 25% of men aged 65, and 55% of men aged 75, irrespective of the fact that the libido of the majority of these patients is relatively unaffected. Annually it results in more than 400,000 outpatient visits and 30,000 hospital admissions in the U.S.. Surgical implantation of penile prosthesis increased from 19,000 in 1980 to 32,000 in 1989. Accordingly, the costs of treating impotence in 1989 is conservatively estimated at 250 million dollars. In human terms, although impotence is not usually a life-threatening situation, its consequences for the patient and his partner are psychologically very serious.
- Atherosclerosis certain types of hypertension, diabetes, heavy smoking and alcoholism are all recognized risk factors for erectile dysfunction.
- Diabetics as a group are the most prone to vasculogenic impotence with more than 50% incidence in a population of about 2.5 million in the USA
- This invention is based on the discovery that effective ameliorative treatment can be based on inducing the penile tissue-specific expression of Nitric Oxide Synthase (NOS), the enzyme which synthesizes the compound nitric oxide (NO), or expressing in vivo the recombinant NOS protein, which NO in turn functions as a mam mediator of penile erection.
- NOS Nitric Oxide Synthase
- NO the enzyme which synthesizes the compound nitric oxide
- NO expressing in vivo the recombinant NOS protein, which NO in turn functions as a mam mediator of penile erection.
- Neurotransmitters are released from three systems: (a) norepineph ⁇ ne from the sympathetic adrenergic fibers; (b) acetylcholine from the parasym pathetic cho nergic fibers; and (c) a substance from the nonadrenergic-noncholinergic (NANC) fibers.
- the NANC neurotransmitter has been shown to be nitric oxide (NO) and to act upon the smooth muscle to cause relaxation.
- the smooth muscle relaxation of the trabeculae surrounding the lacunar spaces of the corpora cavernosa has three important functions: (a) reduction of the normally high resting (flaccid) resistance to arterial flow, thus increasing this flow through the helicene arteries into the endothelium-lined lacunar spaces; (b) regulation of blood storage into the penis, allowing penile engorgement; and (c) transmission of approximately 80% of systolic blood pressure into the cavemosal space.
- the latter will compress the draining venules that run in parallel between the expanding smooth muscle and the tough inelastic tunica albuginea, resulting in venous outflow restriction. Detumescence occurs by a reversal of this process mainly by sympathetic control, that is, an increase of the tone of the smooth muscle in both compartments leading to reduction of arterial inflow and the size of the lacunar spaces, followed by venous runoff.
- NO was identified as the vasoactive compound in the endothelium-der ed relaxing factor (EDRF) and appears to play multiple roles in different biological processes. EDRF is released from the endothelial lining of blood vessels and induces different effects in hypoxia, vascular disease, septic shock, and inflammation. NO plays a significant physiological role in the maintenance of vascular tone by inducing locally the relaxation of the smooth muscle cells. Our work has shown that in the penile corpora cavernosa, NO is the main compound responsible for erection and appears to be the NANC neurotransmitter in the penis.
- EDRF endothelium-der ed relaxing factor
- NANC nerve terminals of the corpora cavernosa, from which it diffuses and then binds to guanyl cyclase in adjacent cells and stimulates the formation of cGMP mainly in the smooth muscle target tissue.
- This cGMP synthesis in turn results in a decrease in intracellular Ca2 + , and subsequent smooth muscle relaxation and penile vasodilation.
- NOS Nitric Oxide Synthase
- cNOS constitutive NOS
- iNOS inducible NOS
- cNOS is classified in several groups: a first is present in brain (one isoform of which is known as neuronal NOS, nNOS, or Type I NOS).
- a second cNOS is present in endothelial cells (endothelial NOS, eNOS or Type III NOS).
- iNOS Type II NOS
- cNOS and iNOS isolated from different tissues show the existence of several isoforms within each group with specific cofactor requirements, mRNA sizes, and immunological properties. More than one isoform may be expressed simultaneously in the same cell type.
- cytosolic isozymes A, present in the brain, cerebellum, and neuroblastoma cells; B, present in endothelial cells; and C, present in neutrophils.
- the first two are calmodulin dependent, and the third is calmodulin independent, lb does not have BH 4 and FAD as cofactors, and la is the only one using FMN additionally as cofactor.
- Ca 2 Vcalmodulin dependent isoform that makes up over 90% of endothelial cell cNOS.
- a soluble type is produced upon induction by macrophages, hepatocytes, Kupfer cells, fibroblasts, endothelial cells, lung and livers in a variety of animal species.
- a different particulate type is present in the macrophages and is only NADPH dependent.
- NOS activity is inhibited by a series of competitive inhibitors such as p-nitro-L-arginine and N c -methyl-L-arginine, or by NO chelators, such as hemoglobin.
- 3-H)citrulline synthesis is increased in certain cells by N-methyl-D-aspartate (NMDA) and glutamate.
- NMDA N-methyl-D-aspartate
- Hydroxy-arginine and arginine dipeptides are also NOS substrates.
- Aminoguanidine appears to be a preferential inhibitor for iNOS, but its specificity varies with the cell type.
- NOS mRNA (and resulting cDNA) are isoform specific and are expressed in a tissue differential fashion.
- nNOS human brain cNOS
- Their mRNA is expressed as a 10.5 kb polynucleotide species. But the same mRNA species is not found in rat kidney, liver, or heart tissue.
- nNOS has been purified from rat polymorphonuclear neutrophiles and other sources.
- the iNOS cDNA has been cloned from bovine and human endothelium. In the latter case, the corresponding cNOS mRNA is 4 kb in length, and is encoded by a gene different from that expressed in the brain.
- iNOS has been cloned from LPS-stimulated rat and mouse macrophages, rat vascular smooth muscle, human hepatocytes and condrocytes. Although only one iNOS gene has so far been identified in each of the species investigated (human, rat, mouse), recent evidence suggests that some of the repeated sequences identified in the human genome may correspond to two or more different genes.
- Induction of non-penile NOS is triggered in vivo in rat and mouse models by injection of lipopolysaccharide from E. Coli (LPS), and in vitro by incubation of cells or tissue strips with LPS, interleukin ⁇ , tumor necrosis factor (TNF- ⁇ ) and/or ⁇ interferon.
- LPS lipopolysaccharide from E. Coli
- TNF- ⁇ tumor necrosis factor
- the induction is protein synthesis- dependent and blocked with dexamethasone or other giucocorticoids, and with TGF- ⁇ .
- NOS activity and it does this in a differential form between intact and castrated rats.
- Voss et al. in U.S. Patent 4,801,587 teaches use of DMSO as an absorption agent to introduce papaverine, a compound known for treatment of human impotence.
- El-Rashidy in U.S. Patent 5,256,625 teaches the use of hydroxy propyl- ⁇ -cyclodextrin as an absorption enhancer for papaverine.
- the main subject of the current invention the penile iNOS isoform
- RPSMC penile smooth muscle cells
- HPSMC human penile smooth muscle cells
- iNOS detection in penile cells It was unknown whether iNOS has any physiological role in erectile function, and there are no publications proposing or suggesting that penile iNOS ever existed or could be applied for the therapy of erectile dysfunction.
- vascular iNOS when induced, may have a deleterious effect on blood pressure. It is assumed to participate in septic shock, without apparently acting on the normal maintenance of blood vessel tone.
- the induction of iNOS, iNOS cDNA or gene therapy to improve penile erection has not been considered before probably because of the risk of systemic hypotension or uncontrollable priapism, and the belief that it does not participate in the natural erectile response.
- no publications on the continuous delivery of compounds into the penis are available as opposed to intermittent treatment modulators. No publications teach the use of the other NOS isoforms (neuronal and endothelial) or their regulation for treating erectile dysfunction.
- the present invention provides a new treatment for erectile dysfunction by the mechanism of raising the level of inducible nitric oxide synthase (iNOS) in the penis by various agents, which in turn, in vivo. effectuates the physiologically controlled production of nitric oxide (NO) to mediate the erectile response by its effect in relaxing the smooth muscle in the corpora cavernosa of the penis.
- iNOS inducible nitric oxide synthase
- This invention is directed to methods and compositions for ameliorating erectile dysfunction in patients through increasing levels of iNOS in penile tissue either by direct introduction of iNOS to penile tissues, or, in the presently preferred embodiment, inducing endogenous production of iNOS by treatment with appropriate iNOS inducers, introduction of iNOS cDNA or by transformation of excised and cultured penile corpora cavemosa cells or tissue pieces with recombinant iNOS cDNA and re-introduction of these cells in the penis in vivo where they proliferate, and improve the NO-producing capability of the corpora cavemosa tissue.
- These procedures are also applicable to use of other NOS isoforms, and their corresponding cDNA, genetically engineered cells, or in vivo gene therapy approaches, in the penis to therapeutically modulate erectile dysfunction.
- FIG. 1 shows schematically the several embodiments of the invention.
- cells or pieces from excised tissue specimen 1 preferably corpora cavemosa cells
- penis 2 are cultured or incubated 3 in appropriate media.
- the cultured Penile Smooth Muscle Cells (PSMC) or corpora cavemosa slices 4 are then treated with inducers 5 appropriate for in vitro induction of iNOS.
- the iNOS 7 from the induced cells or tissue 4 can be extracted, purified 8 and delivered 9 to the penis 2 for treatment.
- the mRNA from in vitro induced PSMC can be isolated 10 and its corresponding cDNA cloned 11, e.g., by RT/PCR (reverse transcription and polymerase chain reaction), library techniques, or other cloning techniques.
- the resulting iNOS cDNA 12 is prepared 13 and delivered 9 to the penis of a patient for treatment.
- the cloned iNOS cDNA 12 can be used to generate recombinant iNOS protein 14 which can be recovered 15 and delivered 9 to the penis 2 for treatment.
- the cultured PSMC cells or tissue pieces 20 are transformed with the recombinant penile iNOS cDNA 12 to produce iNOS engineered cells or corpora cavemosa tissue 22 which are then introduced 24 into appropriate penile tissue 26, such as the corpora cavemosa 28.
- penile tissue 26 such as the corpora cavemosa 28.
- Inducers 16 appropriate for in vivo induction of iNOS can be delivered 9 to the penis 2 of the patient thus raising the level of iNOS endogenously produced in the penile tissue.
- the delivery of NOS biological agents to the penis can be achieved by systemic administration in certain cases, for example, as detailed in Example 10 below.
- RPSMC with a commercially available iNOS antibody.
- an inducer mix such as the one described in detail in Example 2 below comprising E. coli lipopolysaccharide (LPS), recombinant rat interferon- ⁇ (IFN- ⁇ ), recombinant human tumor necrosis factor (TNF- ⁇ ), and recombinant human interleukin-1 ⁇ (IL-1 ⁇ ), to the penile corpora cavemosal tissue of a rat model.
- an inducer mix such as the one described in detail in Example 2 below comprising E. coli lipopolysaccharide (LPS), recombinant rat interferon- ⁇ (IFN- ⁇ ), recombinant human tumor necrosis factor (TNF- ⁇ ), and recombinant human interleukin-1 ⁇ (IL-1 ⁇ )
- LPS E. coli lipopolysaccharide
- IFN- ⁇ recombinant rat interferon- ⁇
- TNF- ⁇ recombinant human tumor necrosis factor
- IL-1 ⁇
- a delivery method involving constant infusion of the inducer mix by means of an osmotic pump attached to a catheter which feeds into the corpora cavemosal tissue is the presently preferred method, although any suitable delivery system can be employed, such as embedded or injected microcapsules, injection of the mix, intraurethral introduction, topical or subdural application, or the like.
- the disclosed pump system can be set to deliver the inducer mix to a rat for a short period (e.g., 1 ul/hr during 3 days) or for a longer treatment period (e.g., 0.5 ul hr during 14 days).
- a short period e.g. 1 ul/hr during 3 days
- a longer treatment period e.g., 0.5 ul hr during 14 days.
- the short-term (ie., 3 day) treatment is more efficacious than the long-term (ie., 14 day) treatment, however this may be an artifact, due to the inactivation of some of the biological constituents in the inducer mix when the mix remains in the pump for extended periods.
- the formulation, delivery system, and scheduled administration should be adjusted for the human patient on a case by case basis.
- the described treatment with iNOS inducers markedly improves the erectile response in in vivo tests performed on rats of three different age groups, adult (5 month old), "old” (20 month old), and "very old” (28-32 month old).
- the erectile responses of the subject rats after completion of the inducer treatment were measured by detecting the maximal intracavernosal pressure in response to electrical field stimulation (EFS) of the cavemosal nerve in the animals. No priapism was observed, indicating that the induced penile iNOS remains under physiological control. No hypertension or other major side effects were detected.
- iNOS induction in the rat corpora cavemosa is also demonstrated ex vivo in incubations of penile slices and determination of iNOS by nitrate and Western Blot assays. This process can also be effected by the presence of the invention ex vivo in incubations of human corpora cavemosa, as shown by similar assays, and in human penile smooth muscle cells (HPSMC) by RT/PCR of the extracted RNA.
- HPSMC human penile smooth muscle cells
- a cDNA library was prepared from induced RPSMC, screened with adequate probes, and several iNOS* clones were detected and sequenced. Com pa ⁇ son of the complete sequence of the RPSMC iNOS coding region showed two distinctive ammo acid differences as compared to the published sequence of rat vascular iNOS, suggesting a distinctive penile iNOS species.
- a construct of RPSMC iNOS was used to stably tranfect RPSMC and the cells constitutively expressed iNOS. A parallel sequence of the HPSMC iNOS was also obtained, confirming iNOS induction in human penile cells and the distinctive nature of the penile iNOS.
- the rat PSMC iNOS construct was used for in vivo gene therapy of impaired corpora cavemosa in aged rats, showing that by a single injection of a liposome-based RPSMC iNOS construct preparation, several rats displayed after five days an erectile response higher than that typically observed even in adult rats.
- iNOS protein produced in vivo was detected by Western Blot. This improvement in erectile response was more uniform (all rats tested) and equally intense after 11 days after the single injection treatment.
- RPSMC iNOS cDNA was prepared in a baculovirus expression vector and iNOS protein was expressed in insect cells Both the transfected cells and tissue pieces, and the iNOS recombinant protein, can be used for increasing penile NO synthesis by direct molecular or implantation in the co ⁇ ora cavemosa.
- the methodology of this invention can be extended to other penile and non-penile NOS isoforms for these and their biological regulators for the treatment of erectile dysfunction.
- Fig. 1 is a schematic illustration of the methods of the invention including use of iNOS and iNOS inducers directly or indirectly to treat human erectile dysfunction;
- Fig. 2 is a series of bar graphs showing the in vitro stimulation of nitric oxide synthesis in cultures of rat penis smooth muscle cells (RPSMC) by treatment with iNOS inducer mixes comprising one lymphokine supplemented with and without bacterial lipopolysaccharide (LPS) as measured by the accumulation of nitrites in the culture medium;
- Fig.3 is a series of bar graphs showing the in vitro stimulation of nitric oxide synthesis in cultures of RPSMC by treatment with iNOS inducer mixes comprising two or three lymphokines plus LPS as measured by the accumulation of nitrites in the culture medium;
- Fig.4 is a line graph showing the time course and stability of the iNOS induction of RPSMC cultures treated with a standard binary INOS inducer mix in the presence or absence of the NOS inhibitor L-NAME as measured by accumulation of nitrites in the culture medium;
- Fig.5 is a bar graph showing that the turnover of the enzyme when the inducers are removed and not replaced is slow thus indicating the persistence of high levels of iNOS for a considerable period after induction
- Fig. 6 is a Northern Blot of poly A+ mRNA from RPSMC submitted to a time-course of induction, as hybridized with a RPSMC iNOS probe;
- Fig. 7 is a Western Blot of an extract obtained by lysis of induced RPSMC and reacted with commercial iNOS antibody;
- Fig. 8 is a line graph showing the uniform improvement in erectile response to electrical field stimulation of the cavemosal nerve in 5, 20, and 30 month old rats treated for three days with a constant infusion of several inducers of the inducible form of penile nitric oxide synthase of this invention;
- Fig. 9 is a bar graph showing increased sensitivity of the erectile response of rats as treated in Fig. 8 to a suboptimal dose of an inhibitor of nitric oxide synthase;
- Fig. 10 is a line graph showing that a medium-term local treatment (14 days) of three age groups with inducers of nitric oxide synthase does not give a better response than the short term paradigm in the enhancement of penile erection triggered by electrical field stimulation;
- Fig. 11 is a bar graph showing that a suboptimal dose of a nitric oxide synthase inhibitor differentiates respondents from non-respondents in the EFS erectile test in rats of different ages;
- Fig. 12 is a bar graph showing the increase in nitric oxide synthase activity in the penile cytosol of rats treated for three days with inducers of nitric oxide synthase;
- Fig.13 is a bar graph showing that the increase in NOS activity in the cytosol of inducer treated rats is inhibited by treatment with L-NAME but is unaffected by treatment with aminoguanidine;
- Figs. 14 A, B and C are photomicrographs of penile tissue showing the increase in NOS activity in the penile tissue of inducer-treated rats as detected by histochemistry;
- Figs. 15 A, B and C are photomicrographs of penile tissue showing the increase in iNOS in the penile tissue of inducer-treated rats as detected by immunocytochemistry;
- Fig. 16 is a Western Blot autoradiogram showing the expression of iNOS protein detected in the co ⁇ ora cavemosa from aged rats subjected to pump infusion of iNOS inducers;
- Fig. 17 is a Western Blot autoradiogram showing that iNOS induction can be obtained ex vivo in the penis, in incubations of slices of rat and human corpora cavemosa where iNOS increase is demonstrated by nitrite release and Western Blot assays;
- Fig. 18 is a sequence overlap map showing the iNOS cDNA clones that were sequenced from a first induced RPSMC library
- Fig. 19 is a sequence comparison showing the iNOS cDNA clones that were sequenced from a second induced RPSMC library and the two clones selected for constructing the iNOS cDNA recombinant representing the whole coding region;
- Fig.20 is a comparative sequencing chart showing the strategy applied to sequence the HPSMC iNOS cDNA, and the comparison of 60% of the HPSMC iNOS coding region with that corresponding to human hepatocyte iNOS cDNA;
- Fig. 21 is a chart showing the primers used for generating the RT PCR fragments from HPSMC iNOS;
- Fig. 22 is a chart showing the homology between the sequence of regions in the RPSMC iNOS cDNA and their counterparts in the human hepatocyte iNOS;
- Fig. 23 are pressure plot charts showing the improvement of the erectile response to EFS in aged rats subjected to gene therapy by direct injection in the corpora cavemosa with a construct of RPSMC iNOS cDNA' and
- Fig. 24 is a Western Blot analysis showing the expression of iNOS protein detected by Western Blots in penile cytosol from aged rats subjected to gene therapy by direct injection in the co ⁇ ora cavemosa with an RPSMC iNOS cDNA construct.
- Measurement of NO production is based on the generation of NO co-products, such as (3-H) citrulline originated from (3-H) L-arginine, or from the relatively stable NO metabolites, such as nitrites and nitrates.
- NO co-products such as (3-H) citrulline originated from (3-H) L-arginine
- NO metabolites such as nitrites and nitrates.
- the latter procedure is particularly suitable for measuring the release and accumulation of the NO-products in the extracellular medium.
- iNos protein can be detected and evaluated by immune-detection in tissue sections (immunocytochemistry) and cytosol (Western Blot), by Northern Blot analysis of its mRNA or by histochemical detection of NOS-associated activity (NADPH diaphorase assay).
- RPSMC penis smooth muscle cells
- Figure 2 presents the results obtained in 48 hr incubations with one cytokine supplemented or not with LPS.
- inducers panel 1 , left bar
- LPS by itself (1 and 10 ug/ml) only marginally stimulate this basal synthesis by less than 50% (panel 1 , central and right bars, respectively).
- INF- ⁇ 50 to 500 U/ml
- LPS left bar
- INF- ⁇ a dose-proportional moderate increase of nitrites to a maximum of 45 uM.
- Supplementation with 1 or 10 ug/ml LPS stimulates the induction up to 120 uM, or nearly 20-fold the basal level.
- TNF- ⁇ up to 500 u/ml did not have any effect either in the presence or the absence of LPS (panels 6 and 7).
- IL-1 ⁇ lnterieukin-1 ⁇
- IL-1 ⁇ lnterieukin-1 ⁇
- IL-1 ⁇ lnterieukin-1 ⁇
- IL-1 ⁇ lnterieukin-1 ⁇
- IL-1 ⁇ lnterieukin-1 ⁇ at the minimum concentration tested (5 ng/ml) in the presence of 10 ug/ml LPS (panel 8, right bar) was slightly more effective than the 500 U/ml dose of INF- ⁇ (panel 8, right bar), but higher concentrations of IL-1 ⁇ up to 100 ng/ml (panels 9, 10), enhanced relatively little the level of stimulation.
- IL-1 ⁇ to 100 U/ml, which only slightly decreases stimulation (panel 15), and by (b) supplementing the latter mix with 500 U/ml TNF- ⁇ , which although prevents this small reduction does not raise the stimulation further (panel 16), IL-1 ⁇ can be lowered to 5 ng/ml and IFN- ⁇ to 100 U/ml (panel 17) with little effect on the induction (compare with panels 14 and 16).
- panel 18 The possibility of reducing IL-1 ⁇ to 5 ng/ml without compromising stimulation is very obvious by comparing panel 18 with the homologous panel 13 where four fold more IL-1 ⁇ was used.
- iNOS mRNA was isolated from RPSMC on two 10 cm dishes by standard guanidium thiocyanate/ CaCI method complemented with two series of phenol/chloroform extractions separated by ethanol precipitation, and polyA-i- RNA was isolation by oligo dT chromatography.
- Northern blots were done with 3-4 ug poly A+ RNA per lane on formaldehyde-denaturing 1 % agarose gels, and subsequent transfer to the nylon membranes with 10X SSC, using the Posiblot pressure blotter.
- Filters were hybridized as we previously described with a [32-P] labeled specific probe we generated consisting of a 350 bp fragment of iNOS cDNA from RPSMC, designated RPSMC-iNOS350. This fragment was synthesized by us by reverse transcription (RT) of 1 ug of polyA+RNA from RP-SMC induced with LPS/ ⁇ INF, using antisense and sense primers N04 and N03, respectively. These primers are 20-mers designed from the nucleotide sequence of the mouse macrophage iNOS and.
- Fig. 6 shows the northern blot of polyA+ from RPSMC submitted to a time-course of induction, as hybridized with our rat PSMC iNOS probe.
- the 4.5 kb typical signal is visible on the top part, and the glyceraldehyde phosphate dehydrogenase reference band on the bottom part.
- Fig. 7 shows the western blot of an extract obtained by lysis of induced RPSMC and reacted with a commercial iNOS antibody, indicating the expected 125-130 KD iNOS band (lane 2). No signal was obtained with a rat cerebellum extract (lane 1). Lane 3 is empty.
- This example demonstrates the method for infusing inducers of nitric oxide synthase directly into the penis in a rat.
- ALZET* osmotic pump Alza Corporation, Palo Alto, CA
- LPS lipopolysaccharide
- INF- ⁇ rat interferon- ⁇
- TNF- ⁇ tumor necrosis factor-(TNF- ⁇ )
- IL-1 ⁇ human interleukin-1 ⁇
- the needle and the tubing were fixed to the penis peripheral tissues by Mersilene 6-0 suture and the osmotic pump was placed subcutaneously on the rat abdomen.
- the needle was pierced into the corpora cavemosa, checking its proper delivery into the lacunar spaces by injection or heparinized saline solution and observation of the mechanically induced erection prior to the final connection with the pump.
- the incision was closed by layer using Dexon 11 Plus 4-0 suture and the success of the operation was checked all throughout the experiment by observation of a normal recovery and urinary activity. These criteria were com pleted by verifying the absence of peripheral hematomas or inflammation when the pum p was removed.
- Each pump delivered the inducer mix by osmotic pressure through the catheter directly into the corpora cavemosa, either at 1 ul/hr during 3 days (pump 1003D) or at 0.5 ul/hr during 14 days (pump 2002).
- pump 1003D was removed from the anesthetized rat at the third day, and a new pump with fresh solution was instilled in the abdomen and connected to the catheter as above. The treatment proceeding until all the content of the reservoir was expelled, for an additional 3 days period.
- This example demonstrates the method for measuring the improvement in erectile response caused by treatment with inducers of nitric oxide synthase.
- rats were anesthetized as in Example 1 and the erectile response was measured by a modification of a published procedure.
- the cavemosal nerve was surgically exposed and stimulated with a square pulse stimulator connected to a platinum bipolar electrode positioned on the nerve.
- a pressure transducer connected to a recorder that was calibrated with a manometer in order to express the response in mm of mercury.
- the animals were reinjected every 45 min with 35 mg/kg of ketamine for the whole duration of the experiment (about 2-3 hours).
- EFS electrical field stimulation
- NOS nitric oxide synthase
- L-NAME N -nitro-L-arginine methy ester
- Fig. 8 shows that there is a significant increase of the erectile response to EFS measured by the maximal intracavemosal pressure at 10 volts in adult and old rats, but a non-significant stimulation in very old rats, treated for three days with the 100 ul pumps (open symbols), as compared with rats of the same ages not submitted to this treatment.
- the stimulation of erectile response is significant in all groups.
- Treatment of the old rats displaying erectile dysfunction with the iNOS inducer mix turns them into better respondents than the younger animals (adult group).
- This considerable enhancement of penile erection found even in non-aged (adult) rats is not accompanied by undesirable side effects.
- the rats look healthy and alert, their systemic blood pressure remains normal, and there is no indication of priapism. This suggests that whatever the mechanism of penile erection enhancement, it remains under physiological control which is released by the EFS stimulus.
- EFS stimulus elicits a nerve transmission process in the penis similar to one or more processes occumng during sexual stimulation, or responsive to sexual stimulus.
- Fig. 9 shows that the stimulation of penile erection in the treated rats is dependent on the NOS cascade, since it is inhibited by sub-optimal doses of L-NAME.
- the fraction of maximal intracavemosal pressure remaining after L-NAME treatment was established and compared with equivalent values in untreated rats previously obtained by us in a separate study.
- the comparative values in the treated and untreated rats were: 39% vs 62% (adult), 18% vs 30% (old), and 28% vs 23% (very old), in the treated vs untreated rats. This indicates that in the adult and old animals the dependence on the NOS cascade upon treatment becomes even higher than in the absence of NOS inducers and in the senescent remains the same.
- Fig. 10 The efficacy of the short-term treatment (3 days) over longer treatments where the inducer mix remains in the pump for 14 days, with the possibility of inactivation of some of the biological constituents, is shown in the experiment depicted on Fig. 10.
- Two groups of rats are apparent in each age group: a) high respondents (solid symbols), with up to 50% and 300% stimulation of the intracavemosal pressure at 10 and 2 volts, respectively, above the respective untreated rats (shown on Fig. 8); b) non-respondents (open symbols), with values similar or below the untreated rats.
- Example 2 Six adult rats were implanted with 100 ⁇ l pumps for 3 days, and then the pumps were replaced by similar ones with fresh solution as indicated in Example 2. Three animals had the pumps containing the inducer mix and three had saline as a control. At the end of the experiment the animals were anesthetized as indicated above and the penis (including the bulb), liver, and in some animals the cerebellum were surgically removed. The penile head and skin were excised and the organs were stored under liquid nitrogen. NOS activity was determined from tissue homogenates from two treated and two control rats, not subjected to EFS in order to avoid the interference with residual L-NAME from the in vivo experiments and
- cytosol fraction was passed through Dowex AG50WX-8 (Na + ) resin to remove endogenous arginine and
- Fig. 14 shows the comparison of frozen sections from untreated rat co ⁇ ora cavemosa from 20 month old animals (panel A), from induced corpora cavemosa from the same age group (panel B), and from the rat cerebellum (panel C).
- IgG using horse radish peroxidase and DAB staining (Fig. 15, all at 100 X magnification)).
- Panel A shows little staining of untreated rat corpora cavemosa with control rabbit serum (1 /1000), whereas the antiserum (1/1000) stains some areas in a more intense brown color (panel B).
- Sections from the treated corpora cavemosa (panel C) have a darker and more difuse staining, as in the case of NADPH diaphorase.
- the immunocytochemical procedure allows a more specific recognition of the iNOS isozyme than the NADPH diaphorase technique (NOS in general), and suggests that iNOS is expressed in the penis from old rats even in the absence of external induction.
- cytosol protein was estimated by a Lowry procedure and 80 ⁇ g of cytosol protein were run on 7.5% polyacrylamide minigels for 1 h and transferred to nylon membranes by electroblotting.
- the iNOS 130 kD band was detected as in the previous example, using 1 h exposure for the autoradiography.
- Fig. 16 (bottom) shows a faint but distinctive iNOS signal in the penile cytosol (CC) from the untreated rats (Ut, first two lanes), which confirms the immunocytochemical results indicating a degree of physiological expression of iNOS in the rat penis, at least in the aged animals.
- CC penile cytosol
- the iNOS signal is considerably enhanced in the penile cytosol from the pump- treated rats (Tr), proving that the in vivo induction was successful.
- No iNOS band is seen in the lanes corresponding to the two negative controls (cerebellum (Ce), and untreated RPSMC), whereas a clear signal occurs in the induced RPSMC cytosol.
- nNOS human brain neuronal NOS
- Transduction Laboratories The membrane was then stripped from the iNOS signal and reacted again with a rabbit antibody against the carboxy term inus of the human brain neuronal NOS (nNOS) (Transduction Laboratories). The corresponding 160 kD species was detected as above, as the top band in a doublet.
- Fig. 16 (top) shows the presence of nNOS in the four penile samples and particularly in the cerebellum cytosol (positive control), and its absence in both untreated and induced RPSMC. This in tum confirms the specificity of the detection with the iNOS antibody.
- EXAMPLE 5 Ex vivo detection of INOS induction in the rat and human corpora cavernosa In order to confirm the capacity of the iNOS inducer mix to elicit iNOS synthesis by direct effect on the rat penis, it is important to demonstrate that iNOS induction can occur in the penile tissue excised from the animal. Similarly, since the ultimate goal is human therapy, it is essential to show that this process can also occur in the human penis. This example shows that iNOS can also be induced by inducer mixes in the corpora cavemosa tissue.
- the skin-denuded bulb and shaft penile regions were excised from three rats, cut in very small pieces, washed several times, and incubated in 24-well plates (50-80 mg/well) in 0.5 ml MEM/10% fetal calf serum. Each penis was divided in four wells, and two of the wells received the standard binary incubation mix (10 ug/ml LPS and 250 U/ml rat ⁇ -interferon). Incubation proceeded for 48 h and nitrites were estimated in the incubation medium. The tissue pieces were washed, homogenized, and the cytosol obtained as in the case of RPSMC in the previous examples. Western blot analysis of iNOS protein was done as above, except that another commercial antibody (Upstate) was used, directed against the whole mouse macrophage iNOS protein. This experiment was repeated three times.
- Fig. 17 top shows the results obtained with the rat co ⁇ ora cavemosa (RCC) in rats 1-3, with (+) or without (-) induction.
- RRC rat co ⁇ ora cavemosa
- An intense 130 kD iNOS band was detectable by Western Blot in the cytosol from the three penises incubated with the inducer mix. The position of the iNOS band was confirmed with cytosol from induced mouse macrophages (IMM, last lane). In two cases (rats 1 and 3), no iNOS band was visible in the absence of inducer, but in one rat (rat 2) there was a substantial endogenous iNOS synthesis, although lower than in the induced samples.
- Nitrite production was evident in all cases, but at low level (44-65 uM m the induced samples). No clear difference in NO synthesis was observed between the + and -lanes, and there was no correlation between the intensity of the iNOS band and nitrite production. This contrasts to what occurs with induced and not induced RPSMC (see above). Similar results were obtained in the replicate experiments (not shown). Fig. 17 bottom shows the results with human penis corpora cavemosa (HPCC). A very intense iNOS band was detected in the third lane of the Westem Blot, corresponding to the induced pieces of HPCC tissue. The positive controls were the cytosols from induced RPSMC (lane 4) and mouse macrophages (IMM, lane 5).
- iNOS can be induced ex vivo in the rat corpora cavemosa, confirming the results obtained in vivo: b) iNOS can also be detected at low levels in some rats in the absence of added inducers, as previously observed in vivo; c) the induced iNOS appears to be subject to a tight control of enzyme activity (inhibition), because nitrite synthesis is very poor and most likely arises from nNOS activity; d) essentially the same process occurs in the human corpora cavemosa.
- iNOS protein or cDNA introduced in the corpora cavemosa by pharmacological means will remain inhibited by a physiological control and will not produce NO until the control is released, e.g., by one or more natural sexual stimulants.
- priapism permanent vasodilation to occur in the treated co ⁇ ora cavemosa
- it explains the absence of priapism in the treatment of rats both with inducers in pumps (Example 3) and with cDNA gene therapy (Example 7).
- EFS cavemosal nerve
- a distinctive penile iNOS cDNA may derive from an iNOS gene, or genes, expressed preferentially in the penis that may be subject to differential expression regulation.
- the enzyme activity of its product iNOS protein
- This example shows the construction and use of a rat iNOS cDNA construct to express constitutively the iNOS protein in RPSMC. Two approaches are presented for making the iNOS constructs.
- This library was plated on 150 cm 2 Petri dishes, cultured, and the lysed plaques were transferred in duplicate (replica plating) to nylon membranes. Hybridization was carried out with the RPSMC-iNOS350 labeled with 32-P. After a primary, secondary and tertiary screening, four clones were selected for sequencing using the dideoxy procedure in an automatic Sequenator. Each sequencing was extended to the 3' direction with the help of successive sequencing primers synthesized on the basis of each previous sequence. Antisense primers allowed sequencing of complementary sequences.
- the library was screened with a mixture of the probes depicted on Fig. 18. Four clones were selected and sequenced as above, as represented on Fig. 19. Only clones 1 and 5, used for the final construct are depicted. Clones 2 and 3 overlap with 5 and slightly extend to the 5' region. The arrows below the iNOS outline show the length and direction of each individual sequencing.
- RPSMC iNOS The overlapping fragments from both cDNA libraries allowed to edit the sequencing errors or ambiguities, and a consensus sequence was finally obtained for RPSMC iNOS (see Appendix A for the nucleotide sequence listing for the RPSMC iNOS cDNA).
- Table I below compiles the nucleotide and amino acid differences found with the sequences of rat vascular iNOS from two different groups, and shows six amino acid differences when matched separately to each one of the reference sequences.
- the number of am ino acid residues which differ from both reference sequences simultaneously is two (amino acids 270 and 591 ) in regions placed upstream from the enzyme active groups.
- Ref # 2 Cloning of iNOS in rat vascular smooth muscle cells. Biochem. Byophys. Resear. Co ., Nuno awa, Y. et al.,1993.
- the ligation mix was used to transform E. coli and the plasmid isolated, purified, analyzed, and designated pBS RPi ⁇ OS.
- the entire i ⁇ OS coding region was then cleaved from pBS RPi ⁇ OS using Kpnl and ⁇ otl and cloned into those cloning sites in the eukaryotic expression vector pcD ⁇ A3 (Invitrogen).
- This vector contains the CMV promoter to direct the transcription of the cloned gene, and SV40-driven neomycin gene conferring resistance to the antibiotic G418.
- the new construct was designated pcDNA3 RPiNOS and sequenced for 150 bp at the 5' end, confirming the presence of iNOS (see Appendix B for the RPSMC iNOS amino acid sequence).
- the construct was then used to stably transform RPSMC in vitro in order to make the cells to constitutively express the iNOS protein in the absence of iNOS inducers.
- pBS RPiNOS was mixed in a 1 :8 ratio (ug/ul) with lipofectin (GIBCO) and added (2 ⁇ g/well) to 1 ml serum -deficient DMEM medium onto 30% confluent RPSMC growing on 35 mm plates. After 5 h DMEM containing 10% fetal calf serum was added and the incubation was allowed to proceed for 24 h. At this time the medium was replaced by fresh one and the incubation continued for 48 h.
- the human penile iNOS In order to transfer to the human the iNOS gene therapy strategy developed in the rat model, the human penile iNOS must be sequenced to determine whether it is the same species or a different one from the human hepatocyte cDNA, and cloned into an adequate expression vector. The latter allows experiments in HPSMC and human corpora cavemosa slices to be conducted prior to human clinical trials. This example shows the relevant partial sequence (60% of the coding region) of the human penile smooth muscle iNOS cDNA
- Specimens of surgically excised corpora cavemosa were obtained from impotent patients undergoing penile prosthesis implantation, and placed in (DMEM) on ice until transport to the laboratory. All procedures were approved by an institutional human subjects committee and carried out under informed consent protocols. The tissue was sliced in very small fragments and used upon 2-6 h of excision for starting up cultures of penile smooth muscle cells (HPSMC) in DMEM with 20% fetal bovine serum using the standard explant method on Primaria flasks. Other tissue pieces were used for direct treatments (see above) without prior smooth muscle cells isolation.
- HPSMC penile smooth muscle cells
- HPSMC human penis smooth muscle cells
- a series of inducers were added at various concentrations, and NO production was measured at 24 and 48 hours by determining the release of nitrites to the medium, using the standard Gness reaction.
- HPSMC from three different patients at passages 4-14 were treated directly in the presence of DMEM 10% fetal bovine serum, whereas in method 2, HPSMC from two of these patients (passage 12) were switched to DMEM with 0.1 % of bovine or human serum, maintained for 24 hours, and finally incubated for another 24 hours in the fresh corresponding medium containing the different inducers.
- LPS lipopolysaccharide
- IFN- ⁇ interferon-gamma
- TNF- ⁇ tumor necrosis factor-a
- IL-1B recombinant human ⁇ nterleuk ⁇ n-1 ⁇ Due to the relatively low iNOS induction in HPSMC, this cDNA library is not the preferred method.
- the preferred method was changed from the cDNA library approach applied to induced RPSMC, to one based on reverse transcription (RT) of the iNOS mRNA combined with the amplification by polymerase chain reaction (PCR) of the resulting cDNA
- RT reverse transcription
- PCR polymerase chain reaction
- a se ⁇ es of 18 twentymer primers were synthesized by a standard procedure using the published sequence of the human hepatocyte iNOS cDNA, for RT/PCR and DNA sequencing reactions. They were chosen so that each one of the sense primers (except No. 1) is 100-150 bp upstream of the immediately preceding antisense primer, encompassing a unique rest ⁇ ction site in each of the different fragments (0.35-0.95 kb). This facilitates the subsequent cloning of the amplified fragments.
- Fig. 20 shows the location of the HPSMC iNOS cDNA that has been sequenced.
- Fig. 20 shows the location of the HPSMC iNOS cDNA that has been sequenced.
- Two anti-human hepatocyte iNOS antibodies designated Ab1 and Ab 2 were prepared in rabbits against synthetic small peptides (15 amino acids each) in those regions.
- Fig. 21 shows the primers utilized for generating the RT/PCR fragments from HPSMC that were sequenced.
- Fig.22 shows that the homologies between the HPSMC iNOS nucleotide sequences and the respective human hepatocyte iNOS varies from 88% to 99% according to the region.
- the homology of HPSMC iNOS to the rat aorta iNOS is only 81 -82%. Even considering ambiguities and sequencing errors, this suggests that the HPSMC sequences so far obtained belong to a different cDNA than that for the human hepatocyte iNOS, in agreement to the situation obtained with RPSMC iNOS.
- RPSMC and HPSMC iNOS cDNAs are coded by different gene(s) than the rat and human iNOS gene(s) so far discovered does not affect the use of the iNOS gene therapy or iNOS protein therapy procedures of this invention.
- This example shows the procedure used to clone the penile iNOS from the corpora cavemosa smooth muscle and the sequence of a penile-specific new iNOS isoform.
- the corresponding construct has been expressed in rat penile cells that are able to constitutively synthesize NO.
- one method of this invention comprises implanting iNOS stably transfected penile cells or pieces of corpora cavemosa into the penis of men with erectile dysfunction, in order to increase NO synthesis upon sexual stimulation and improve the erectile response.
- penile iNOS from the human corpora cavemosa smooth muscle has been partially sequenced and is believed to be a distinct penile isoform. (See Appendix C, and the corresponding cDNA sequence Appendix D.)
- EXAMPLE 8 Correction of erectile dysfunction the aged rat bv gene therapy of the corpora cavemosa with rat penile iNOS cDNA
- iNOS can ameliorate the erectile dysfunction in aged rats
- This example shows that gene therapy of erectile dysfunction in a rat model using the RPSMC iNOS cDNA construct significantly and unexpectedly improves erectile response.
- Fig.24 shows a very distinctive iNOS band in the corpora cavemosa of rat #1, a fainter one in rat #2, and none in rats #3 and 4#, which is expected from the results of the erectile response.
- Three of the controls (#2,#3,#4) had little or no iNOS expression, also agreeing with the erectile response. However, one control (#1 ) had an apparently spurious high iNOS not consistent with the erectile response.
- Example 8 shows that a single injection of our construct given directly in the corpora cavemosa was able in two aged rats out of the three tested to improve dramatically the EFS erectile response 5 days after the injection, and to elicit penile iNOS expression, without causing side effects.
- the response after a much longer period to allow for a higher iNOS expression, and using a lower dose to minimize side- effects, was even better and more reproducible.
- gene therapy of impotence may be performed in the patient by self-injection directly in the co ⁇ ora cavemosa. However, the patient only needs to self-administer these injections only periodically (at a frequency proportional to the stability of NOS expression).
- the invention includes a procedure employing inoculation of the recombinant penile iNOS protein directly into the corpora cavemosa
- This "foreign" iNOS enzyme becomes active only when sexual stimulus triggers the initial erectile response.
- endogenous iNOS synthesized from induced iNOS mRNA or from transfected recombinant iNOS shows methods of production of large amounts of penile iNOS protein for use in erectile dysfunction therapy.
- the 5' region of the RPINOS gene was removed by PCR. Efficient expression of genes from the polyhedron promoter on pVL1393 requires that the ATG translational start sequence be within 80 base pairs the polyhedron promoter.
- the cloned RPINOS gene has a 142 bp 5' untranslated region. We chose to remove this region by performing PCR on the RPINOS gene using primers matching the polyhedron promoter-Bam HI restriction site and an internal region of RPINOS spanning a BsaAI restriction site. This 254 bp PCR fragment was next cloned into the pCRII cloning vector by the TA cloning technique. The plasmid pCRII-BamHI-BsaAI was cut with BamHI and BsaAI restriction enzymes and the BamHI-BsaAI fragment was used later for a ligation reaction.
- the second step was to isolate the 3' region of RPINOS and the baculovirus transfer vector
- Plasmid pBSRPINOS was cut with BsaAI and Notl to liberate a 3.8 KB fragment that was subsequently purified for cloning purposes.
- pVL1393 was cut with BamHI and Notl restriction enzymes and purified. The fragments were then linked together by first ligating the 254 bp BamHI-BsaAI fragment with the 3.8 KB RPINOS 3' region fragment. This product was isolated by gel electrophoresis and subsequently ligated to pVLl393 (BamHI and Notl cut). The composite plasmid, pVLRPiNOS, was transformed into E.
- coli and the correct ligation product was identified by colony hybridization using separately the 254 bp BamHI-BsaAI fragment and an internal RPINOS gene fragment.
- the cloning was further corroborated by restriction digestion and DNA sequencing of the RPiNOS ATG region.
- the gene For expression of RPiNOS in insect cells, the gene must be moved into the baculovirus genome by homologous recombination. This was done by co-infection of Sf9 insect cells with the transfer plasmid pVLRPiNOS and a deletion version of baculovirus AcNPV (Baculogold, sold by Pharmigen). The modified virus allows positive selection for recombinants.
- virions were purified by a plaque assay. Four of these pure isolates were amplified twice to obtain high titer stocks. Viral stocks were analyzed for expression of iNOS by a variety of methods. First, PCR on viral supematants and infected cell cytosols to identify which are correctly recombined. Second, Westem
- iNOS a high level baculovirus producer of iNOS infected a large culture of Sf9 cells grown in spinner flasks.
- the iNOS is purified by 2* 5' ADP-ribose affinity chromatography, which yields an approximately 95% purified protein, which is useful for in vivo gene therapy experiments in the rat.
- the corresponding human penile iNOS, produced by the same method is useful in in vivo gene therapy in human patients.
- erectile dysfunction In order to demonstrate the usefulness of iNOS therapy for different types of erectile dysfunction, it is important to determine in each case whether endogenous penile NOS is actually decreased and at what level of NOS expression the impairment occurs.
- the rat model of erectile dysfunction allows for the systematic determination of erectile function and penile NOS. This example shows that erectile dysfunction in the rat model is ordinarily accompanied by a decrease in penile NOS.
- NC no change
- NC/- non-significant 20-30% decrease
- - 40-50% decrease
- -- more than 60% decrease.
- the erectile function was measured by EFS as above, and, in the BB rats only, by determining the erectile reflexes upon manipulation of the penis in the restrained non-anesthetized animal (number of cups and flips). The first detects cavemosal nerve compromise and the second peripheral neuropathies (dorsal nerve). With the exception of passive smoking, all other treatments or conditions impaired one or the other of the erectile parameters, showing a clear erectile dysfunction that can be used as a model for the corresponding situation in men (Fig. 25).
- Penile NOS activity was measured in the cytosol by the L-arginine/citrulline conversion assay, as described in previous examples. In all cases without exception (Fig. 25), there was 50% or higher penile NOS reduction. Penile NOS content (the amount of NOS protein present, irrespective of its activity) was visualized by Western Blot and estimated by a semi-quantitative densitometric assay with a suitable conventional computer program. An antibody against the human nNOS isoform was used throughout because nNOS is the only isoform previously known to be naturally occumng in the penis.
- penile nNOS content (Table II) was unaffected, thus suggesting that an androgen-dependent inhibition of NOS activity is the main cause of the erectile dysfunction, coupled with other effects on the erectile mechanism.
- penile nNOS In the long-term conditions, involving neuropathies and fibrosis of the penile tissue, there is a clear reduction of penile nNOS. This includes one situation (smoking) where erection is not affected, probably because a compensatory mechanism based on non NO-ancillary pathways is activated during a long-term process.
- Inducer mixes of the type presented under Examples 3 and 4, cannot be applied systemically because of the risk of general induction of iNOS in organs other than the penis and the resulting systemic effects if iNOS is activated in each organ.
- the inducer mix is delivered directly into the co ⁇ ora cavemosa in a continuous fashion for a short period (few days), because of the potential unstability of the cytokines. The effect will not be immediate, but last for a period ranging from a few days to weeks, and may require repeated administration.
- Penile specific iNOS cDNA preparations are based on: a) non-targeted, non-organ or tissue specific expression constructs, in liposome or other suitable pharmacologically acceptable formulations (indicated with — on Table III); or b) organ or tissue specific expression constructs, in adenovirus or retrovirus formulations (indicated with TS on Table III). Both types of constructs are intended to provide a non-immediate medium -duration effect, depending on the stable expression of an episomal or integrated foreign iNOS cDNA for days, weeks or months, mainly through intermittent applications.
- the liposome formulations include a vector of the type presented under Examples 7 or 8, or other equivalent formulations with effective features and different lipid complexes, which may be expressed at low levels anywhere in the organism. Therefore, they are intended for direct penile application to avoid general effects.
- the adenovirus constructs provide a much more efficient transfer to even non-replicating cells, as those in the penile smooth muscle. These constructs also may be administered systemically, if a specific promoter assures preferential expression in the penis. For exam pie, the constructs may be used with We propose the use of the smooth muscle ⁇ -actin, the collagen, or alike, promoters, in order to target expression in the smooth muscle.
- the foreign iNOS protein will be restricted to fibrotic vascular tree (aging-related) and within this compartment it will only be functional in the penis, either because it requires activation by neurotransmitters released in the penis during sexual stimulation or because it represents a specific penile iNOS. Expression in other smooth muscle containing organs may also occur.
- replicating HPSMC in culture may be transformed by iNOS constructs in retroviral vectors, which may provide an even more efficient and stable integration, since retrovirus will induce the permanent modification of the HPSMC genome.
- Penile smooth muscle cells stably transfected with iNOS constructs, of the type presented under Examples 6 and 7. They are transformed in vitro with either liposome, adenovirus, retrovirus, or similar, constructs, and then implanted in vivo locally in the corpora cavemosa, preferably at multiple locations to help insure uniform distribution and more effective production throughout the HPCC. No systemic administration is deemed feasible.
- This class of products provides a very targeted, highly organ-specific expression, with non-immediate sustained effects of the type described for class B (Ba and Bb in Table III).
- Cell cultures (HPSMC) obtained from the same patient may be preferred or even necessary, but stable cultures from a single source are expected to be functional according to the implant procedure.
- Penile corpora cavemosa tissue transformed as for class C (Table III). They are particularly suited for direct implantation, a procedure where single cells are not adequate (see below). Likewise, the iNOS transfected corpora cavemosa pieces may be administered and work as for class C.
- the recombinant iNOS protein made and purified as under Example 9, or the endogenous penile iNOS, may be applied, mainly locally.
- the intended use is for a short and immediate effect of the type obtained with locally administered vasodilators, as opposed to the other four classes.
- the protein is relatively unstable (limited shelf life), and requires repeated administration (non-stable transformation). Systemic routes would require that the protein is only active in the penis.
- the specific routes of administration can be classified as follows: I) Systemic: restricted to targeted iNOS cDNA (adenovirus/tissue or organ specific promoter), and potentially to iNOS protein. It is self-adm mistered by the patient, and may be either: 1) oral (preferentiaO, or 2) subcutaneous or intravenous injection. In the case of the cDNA it is expected to may require intermittent repetition, but not linked to the moment of sexual intercourse. In the case of the protein, administration would have to be immediately before sexual intercourse.
- Example 6 1) Direct self-injection into the base of a temporarily constricted co ⁇ ora cavemosa, as under Example 6, using the procedure applied for vasoactive compounds. This procedure is reserved for iNOS constructs, and may be for transfected HPSMC, although the latter may colonize locations other than the penis. It is also suitable for iNOS protein. The injection is done intermittently and at a timing independent from sexual intercourse, except for the iNOS protein.
- Retroviral vectors are preferred for genom ic integration and the procedure is independent from sexual intercourse.
- Single cells are maintained together in artificial compartments seeded in the corpora cavemosa, avoiding cell dispersion by the circulation.
- the carrier material may facilitate tissue colonization (degradable pellets), or create a physical semipermeable barrier between the transplanted cells and the host immune system (microcapsules of alginate or equivalents; dialysis membrane compartments; etc.). This is expected to provide the longest duration of effects.
- nNOS and eNOS-related biological agents for the treatment of erectile dysfunction are readily applicable for nNOS and eNOS-related biological agents.
- the main differences are that no inducer treatment will be applicable because these are constitutive isozymes, and that the exogenous material will be subjected to the same physiological regulation affecting the endogenous nNOS, and possibly eNOS, in the penis.
- nNOS and eNOS may be warranted in those cases presented under Example 8, where nNOS (and possibly eNOS) content is not affected by the pathological condition.
- modulators may include NOS co-factors (tetrahydrobiopterine, coenzymes, etc), substrate (L-arginine), dimerization inducers, and related materials, to be applied locally in the penis.
- NOS co-factors tetrahydrobiopterine, coenzymes, etc
- substrate L-arginine
- dimerization inducers dimerization inducers, and related materials, to be applied locally in the penis.
- the preferred embodiment of our invention is based on the in vivo local continuous treatment of the penis with a mix of iNOS inducers by single or repeated local administration of constructs of iNOS, cDNA, or iNOS recombinant protein; or implants of genetically engineered penile cells or tissues hyperexpressing iNOS, to produce a considerable stimulation of the erectile response accompanied by an increase of penile NOS, which our evidence shows is the iNOS isozyme.
- the localized in vivo treatment surprisingly does not cause undesirable side effects that would be expected from systemic administration of iNOS inducers, and keeps the penile NOS actively under physiological control since no erection (priapism) is elicited in the absence of nerve stimulation.
- the demonstration and characterization of iNOS at the mRNA and protein levels in cells and tissue from the rat and human co ⁇ ora cavemosa smooth muscle indicates that this unique isozyme plays a physiological role in the penis, and permits cloning its cDNA
- penile cNOS is a distinct isozyme or species from other rat iNOS, including the vascular smooth muscle.
- our invention includes use of the corresponding recombinant iNOS cDNA, and those obtained from other species and penile cell types, which are effective in increasing NOS synthesis in the penis under physiological control.
- Our invention provides an improved method for raising penile NOS levels to treat erectile dysfunction case.
- the scope of this invention may be extended to the treatment of erectile dysfunctions by administering locally to the penis: (a) constructs of nNOS or eNOS; (b)their respective CDNAs; (b) their respective proteins; (c) penile or tissue genetically engineered to express nNOS or eNOS; or (d) biological modulators of NOS activity, in such a way that they remain under psychological control and do not cause undesirable side effects.
- a systemic administration is also proposed for certain cases, preferably in association with tissue specific regulators.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8516199A JPH11501206A (en) | 1994-11-10 | 1995-11-09 | Improvement of human erectile dysfunction by treatment with iNOS and related NOS agents |
AU42336/96A AU693621B2 (en) | 1994-11-10 | 1995-11-09 | Amelioration of human erectile dysfunction by treatment with iNOS, and related NOS agents |
EP95940665A EP0808104A1 (en) | 1994-11-10 | 1995-11-09 | AMELIORATION OF HUMAN ERECTILE DYSFUNCTION BY TREATMENT WITH iNOS, AND RELATED NOS AGENTS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/337,357 US5594032A (en) | 1994-11-10 | 1994-11-10 | Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA |
US08/337,357 | 1994-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996014748A1 true WO1996014748A1 (en) | 1996-05-23 |
Family
ID=23320240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/014588 WO1996014748A1 (en) | 1994-11-10 | 1995-11-09 | AMELIORATION OF HUMAN ERECTILE DYSFUNCTION BY TREATMENT WITH iNOS, AND RELATED NOS AGENTS |
Country Status (7)
Country | Link |
---|---|
US (1) | US5594032A (en) |
EP (1) | EP0808104A1 (en) |
JP (1) | JPH11501206A (en) |
CN (1) | CN1174493A (en) |
AU (1) | AU693621B2 (en) |
CA (1) | CA2204886A1 (en) |
WO (1) | WO1996014748A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1005538A1 (en) * | 1997-02-13 | 2000-06-07 | Albert Einstein College Of Medicine Of Yeshiva University | Gene therapy for alleviating erectile dysfunction |
WO2002053143A2 (en) * | 2001-01-05 | 2002-07-11 | The Medical College Of Georgia Research Institute, Inc. | Treatment of erectile dysfunction with rho-kinase inhibitors |
JP2003501345A (en) * | 1999-01-21 | 2003-01-14 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | Use of vascular endothelial growth factor in the treatment of erectile dysfunction |
AU757803B2 (en) * | 1998-08-18 | 2003-03-06 | Albert Einstein College Of Medicine Of Yeshiva University | Gene therapy for regulating smooth muscle cell tone |
US7030096B1 (en) | 1997-02-13 | 2006-04-18 | Albert Einstein College Of Medicine Of Yeshiva University | Method of enhancing relaxation of penile smooth muscle by introduction of DNA encoding maxi-K potassium channel protein |
JP2009143968A (en) * | 1997-09-17 | 2009-07-02 | Strategic Science & Technologies Inc | Delivery of arginine to cause beneficial effect |
US7629384B2 (en) | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US7914814B2 (en) | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
EP2300604A1 (en) * | 2008-06-24 | 2011-03-30 | Micropharma Limited | Nitric oxide compositions and devices and methods for cosmesis |
US9050365B2 (en) | 2004-04-19 | 2015-06-09 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US9072659B2 (en) | 2009-06-24 | 2015-07-07 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
US9155701B2 (en) | 2009-06-24 | 2015-10-13 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1850997A (en) * | 1996-02-15 | 1997-09-02 | Nestor F Gonzalez-Cadavid | Novel penile neuronal nitric oxide synthase (pnnos) and applications for diagnosis and treatment of urogenital disorders |
CA2248558A1 (en) * | 1996-03-15 | 1997-09-18 | Yale University | Methods and means of detecting nitric oxide synthase |
EP0864648B1 (en) * | 1996-09-20 | 2006-11-29 | Daiichi Asubio Pharma Co., Ltd. | Method for screening compounds regulating the expression of human-inducible nitric oxide synthase |
US6271211B1 (en) | 1997-02-13 | 2001-08-07 | Albert Einstein College Of Medicine Of Yeshiva University | Gene therapy for regulating penile smooth muscle tone |
US6239117B1 (en) | 1997-02-13 | 2001-05-29 | Albert Einstein College Of Medicine Of Yeshiva University | Gene therapy for regulating bladder smooth muscle tone |
US20020055702A1 (en) * | 1998-02-10 | 2002-05-09 | Anthony Atala | Ultrasound-mediated drug delivery |
AU3221599A (en) * | 1998-04-03 | 1999-10-25 | Daily Wellness Company, The | Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation |
US6866842B1 (en) * | 1998-05-01 | 2005-03-15 | University Of Pittsburgh | Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction |
ATE369141T1 (en) * | 1998-05-01 | 2007-08-15 | Univ Pittsburgh | CELL-MEDIATED GENE ADMINISTRATION BY USING MUSCLE-DERIVATED CELLS TO TREAT THE BONE-RELATED INJURY OR DISORDER |
US7115417B1 (en) | 1998-05-01 | 2006-10-03 | Chancellor Michael B | Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof |
US6436997B1 (en) | 1998-06-01 | 2002-08-20 | Nitromed, Inc. | Endogenous nitric oxide synthesis under conditions of low oxygen tension |
US6277884B1 (en) * | 1998-06-01 | 2001-08-21 | Nitromed, Inc. | Treatment of sexual dysfunction with N-hydroxyguanidine compounds |
US5942545A (en) * | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
FR2786699B1 (en) * | 1998-12-02 | 2002-10-04 | Philippe Gorny | MEDICINE, IN PARTICULAR FOR PREVENTING OR TREATING SEXUAL DYSFUNCTIONS |
US6650943B1 (en) | 2000-04-07 | 2003-11-18 | Advanced Bionics Corporation | Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction |
AU2001251599B2 (en) * | 2000-04-14 | 2006-03-02 | University Of Pittsburgh | Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof |
US6620616B1 (en) | 2000-09-13 | 2003-09-16 | The Cleveland Clinic Foundation | Nucleic acids encoding nitric oxide synthase variants |
US6497885B2 (en) * | 2000-12-22 | 2002-12-24 | The Daily Wellness Company | Method and composition for improving fertility health in female and male animals and humans |
US6989164B2 (en) | 2000-12-22 | 2006-01-24 | The Daily Wellness Company | Method and composition for improving male fertility health |
CA2438904C (en) * | 2001-02-23 | 2012-09-04 | The University Of Pittsburgh | Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair |
US20050240229A1 (en) * | 2001-04-26 | 2005-10-27 | Whitehurst Tood K | Methods and systems for stimulation as a therapy for erectile dysfunction |
US6885895B1 (en) * | 2001-04-26 | 2005-04-26 | Advanced Bionics Corporation | Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction |
US6706756B1 (en) | 2001-11-16 | 2004-03-16 | University Of South Florida | Vasodilating compound and method of use |
CN103230415B (en) * | 2003-04-25 | 2016-05-04 | 匹兹堡大学联邦制高等教育 | For promoting and strengthen the neural muscle derived cell (MDC) of repairing and regenerating |
US8105834B2 (en) * | 2007-01-11 | 2012-01-31 | University of Pittsburgh—of the Commonwealth System of Higher Education | Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using same |
ES2382022T3 (en) * | 2007-06-13 | 2012-06-04 | Wake Forest University Health Sciences | Erectile function restoration procedures |
AU2009282619B2 (en) * | 2008-08-18 | 2015-08-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof |
US20100233138A1 (en) * | 2008-11-07 | 2010-09-16 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Vocal Cord Augmentation Utilizing Muscle-Derived Progenitor Compositions, and Treatments Thereof |
US20120093950A1 (en) | 2010-10-19 | 2012-04-19 | Klrm, Llc | Compositions and methods for treating, inhibiting the onset, and slowing the progression of erectile dysfunction including naturally occuring age related erectile dysfunction |
CN108042548B (en) * | 2018-02-01 | 2020-05-08 | 贵阳中医学院第一附属医院 | Application of tanshinone IIA sodium sulfonate in preparation of medicine for treating erectile dysfunction |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
US4931445A (en) * | 1988-10-06 | 1990-06-05 | Irwin Goldstein | Agents for treatment of male impotence |
IT1252603B (en) * | 1990-04-19 | 1995-06-19 | Giorgio Cavallini | 2,4-DIAMINO-6 PIPERIDINO PIRIMIDINA-3 TOPICAL OXIDE ON THE GLAND IN THE TREATMENT OF ERECTILE IMPOTENCES |
US5268465A (en) * | 1991-01-18 | 1993-12-07 | The Johns Hopkins University | Purification and molecular cloning of nitric oxide synthase |
US5132407A (en) * | 1991-09-26 | 1992-07-21 | Cornell Research Foundation, Inc. | Purified inducible nitric oxide synthase flavoprotein |
US5278192A (en) * | 1992-07-02 | 1994-01-11 | The Research Foundation Of State University Of New York | Method of vasodilator therapy for treating a patient with a condition |
WO1994016729A1 (en) * | 1993-01-28 | 1994-08-04 | Neorx Corporation | Targeted nitric oxide pathway or nitric oxide synthase modulation |
-
1994
- 1994-11-10 US US08/337,357 patent/US5594032A/en not_active Expired - Fee Related
-
1995
- 1995-11-09 EP EP95940665A patent/EP0808104A1/en not_active Ceased
- 1995-11-09 CA CA002204886A patent/CA2204886A1/en not_active Abandoned
- 1995-11-09 WO PCT/US1995/014588 patent/WO1996014748A1/en not_active Application Discontinuation
- 1995-11-09 CN CN95197487A patent/CN1174493A/en active Pending
- 1995-11-09 AU AU42336/96A patent/AU693621B2/en not_active Ceased
- 1995-11-09 JP JP8516199A patent/JPH11501206A/en active Pending
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, issued 1994, EHREN et al., "Nitric Oxide Synthase Activity in the Human Urogenital Tract", Abstract No. 122:259288. * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1005538A4 (en) * | 1997-02-13 | 2002-12-04 | Einstein Coll Med | Gene therapy for alleviating erectile dysfunction |
EP1005538A1 (en) * | 1997-02-13 | 2000-06-07 | Albert Einstein College Of Medicine Of Yeshiva University | Gene therapy for alleviating erectile dysfunction |
US7030096B1 (en) | 1997-02-13 | 2006-04-18 | Albert Einstein College Of Medicine Of Yeshiva University | Method of enhancing relaxation of penile smooth muscle by introduction of DNA encoding maxi-K potassium channel protein |
JP2009143968A (en) * | 1997-09-17 | 2009-07-02 | Strategic Science & Technologies Inc | Delivery of arginine to cause beneficial effect |
US7914814B2 (en) | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
US7629384B2 (en) | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
AU757803B2 (en) * | 1998-08-18 | 2003-03-06 | Albert Einstein College Of Medicine Of Yeshiva University | Gene therapy for regulating smooth muscle cell tone |
JP2003501345A (en) * | 1999-01-21 | 2003-01-14 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | Use of vascular endothelial growth factor in the treatment of erectile dysfunction |
WO2002053143A3 (en) * | 2001-01-05 | 2008-01-03 | Med College Georgia Res Inst | Treatment of erectile dysfunction with rho-kinase inhibitors |
WO2002053143A2 (en) * | 2001-01-05 | 2002-07-11 | The Medical College Of Georgia Research Institute, Inc. | Treatment of erectile dysfunction with rho-kinase inhibitors |
US9050365B2 (en) | 2004-04-19 | 2015-06-09 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
EP2300604A1 (en) * | 2008-06-24 | 2011-03-30 | Micropharma Limited | Nitric oxide compositions and devices and methods for cosmesis |
EP2300604A4 (en) * | 2008-06-24 | 2011-07-27 | Micropharma Ltd | Nitric oxide compositions and devices and methods for cosmesis |
US9155701B2 (en) | 2009-06-24 | 2015-10-13 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US10682357B2 (en) | 2009-06-24 | 2020-06-16 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9072659B2 (en) | 2009-06-24 | 2015-07-07 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9457092B2 (en) | 2009-06-24 | 2016-10-04 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US9463158B2 (en) | 2009-06-24 | 2016-10-11 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9492458B2 (en) | 2009-06-24 | 2016-11-15 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9161915B2 (en) | 2009-06-24 | 2015-10-20 | Strategic Science & Technologies, Llc | Delivery of ibuprofen and other compounds |
US9675619B2 (en) | 2009-06-24 | 2017-06-13 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9737543B2 (en) | 2009-06-24 | 2017-08-22 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US10898489B2 (en) | 2009-06-24 | 2021-01-26 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US10172865B2 (en) | 2009-06-24 | 2019-01-08 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9498482B2 (en) | 2010-12-29 | 2016-11-22 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9833456B2 (en) | 2010-12-29 | 2017-12-05 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
US9289495B2 (en) | 2010-12-29 | 2016-03-22 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
Also Published As
Publication number | Publication date |
---|---|
AU693621B2 (en) | 1998-07-02 |
CN1174493A (en) | 1998-02-25 |
JPH11501206A (en) | 1999-02-02 |
EP0808104A1 (en) | 1997-11-26 |
CA2204886A1 (en) | 1996-05-23 |
US5594032A (en) | 1997-01-14 |
AU4233696A (en) | 1996-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU693621B2 (en) | Amelioration of human erectile dysfunction by treatment with iNOS, and related NOS agents | |
Garban et al. | Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction | |
Katsuura et al. | Involvement of organum vasculosum of lamina terminalis and preoptic area in interleukin 1 beta-induced ACTH release | |
Ramamoorthy et al. | Regulation of the human serotonin transporter by interleukin-1β | |
Tsujino et al. | Induction of nitric oxide synthase gene by interleukin-1 beta in cultured rat cardiocytes. | |
Lanni et al. | 3, 5‐diiodo‐L‐thyronine powerfully reduces adiposity in rats by increasing the burning of fats | |
Pepper et al. | Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. | |
Nilsson et al. | Imprinting of female offspring with testosterone results in insulin resistance and changes in body fat distribution at adult age in rats. | |
Akabayashi et al. | Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion | |
Li et al. | TNF‐α increases ubiquitin‐conjugating activity in skeletal muscle by up‐regulating UbcH2/E220k | |
Nishiya et al. | Effects of erythropoietin on cardiac remodeling after myocardial infarction | |
Wu et al. | Endothelial-dependent vascular effects of insulin and insulin-like growth factor I in the perfused rat mesenteric artery and aortic ring | |
Tzeng et al. | Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects on myointimal hyperplasia | |
Sakaguchi et al. | Intrahypothalamic injection of insulin decreases firing rate of sympathetic nerves. | |
US6780836B2 (en) | Method of promoting angiogenesis using relaxin | |
Ono et al. | Induction of Mn-superoxide dismutase by tumor necrosis factor, interleukin-1 and interleukin-6 in human hepatoma cells | |
Mühl et al. | Cyclosporin derivatives inhibit interleukin 1β induction of nitric oxide synthase in renal mesangial cells | |
Muhs et al. | Preclinical evaluation of inducible nitric oxide synthase lipoplex gene therapy for inhibition of stent-induced vascular neointimal lesion formation | |
Jeejeebhoy et al. | Effects of hormones on the synthesis of α1 (acute-phase) glycoprotein in isolated rat hepatocytes | |
Vesely | Metabolic targets of cardiac hormones' therapeutic anti-cancer effects | |
Gong et al. | Lipolysis and apoptosis of adipocytes induced by neuropeptide Y-Y5 receptor antisense oligodeoxy-nucleotides in obese rats | |
Teyssot et al. | Induction of casein synthesis by prolactin and inhibition by progesterone in the pseudopregnant rabbit treated by colchicine without any simultaneous variations of casein mRNA concentration | |
US6486134B2 (en) | Gene treatment to enhance feed efficiency and growth rate of livestock | |
Ishihara et al. | Effects of diet and time of the day on serum and CSF leptin levels in Osborne‐Mendel and S5B/Pl rats | |
Banerjee et al. | Feminization imprinted by developmental growth hormone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95197487.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KP KR LK LR LT LV MD MK MX NO NZ PL RO RU SI SK TT UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2204886 Country of ref document: CA Ref document number: 2204886 Country of ref document: CA Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 1996 516199 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995940665 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 1995940665 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1995940665 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995940665 Country of ref document: EP |